Protein kinase C (PKC) modulates growth, differentiation, and apoptosis in a cell-specific fashion. Overexpression of PKC-a in MCF-7 breast cancer cells (MCF-7-PKC-a cell) leads to expression of a more transformed phenotype. The response of MCF-7 and MCF-7-PKC-c cells to phorbol esters (TPA) was examined. TPA-treated MCF-7 cells demonstrated a modest cytostatic response associated with a G, arrest that was accompanied by Cipl expression and retinoblastoma hypophosphorylation. While p53 was detected in MCF-7 cells, evidence for TPA-induced stimulation of p53 transcriptional activity was not evident. In contrast, TPA treatment induced death of MCF-7-PKC-a cells. Bryostatin 1, another PKC activator, exerted modest cytostatic effects on MCF-7 cells while producing a cytotoxic response at low doses in MCF-7-PKC-a cells that waned at higher concentrations. TPA-treated MCF-7-PKC-a cells accumulated in G2/M, did not express p53, displayed decreased Cipl expression, and demonstrated a reduction in retinoblastoma hypophosphorylation. TPA-treated MCF-7-PKC-a cells expressed gadd45 which occurred before the onset of apoptosis. Thus, alterations in the PKC pathway can modulate the decision of a breast cancer cell to undergo death or differentiation. In addition, these data show that PKC activation can induce expression ofgadd45 in a p53-independent fashion. (J.
Introduction
The protein kinase C (PKC)1 gene family lies on signal transduction pathways regulating growth and differentiation in a variety of cell types ( 1, 2) . In addition, activation of this signaling pathway modulates induction of apoptosis in a cell-specific fashion. In certain cells, phorbol ester-stimulated activation of PKC inhibits apoptosis while in other cells a death program is initiated by activation of PKC (3) (4) (5) (6) (7) . Beyond describing the ability of PKC to modulate apoptosis, little is known of the mechanisms either within the PKC pathway or signaling cascades distal to PKC that are responsible for producing these disparate, cell-specific responses. The existence of at least 12 members in the PKC gene family may, in part, serve as a mechanism responsible for the diverse responses elicited by activating this pathway ( 1, 2) . Differences in substrate specificity, subcellular localization, and sensitivity to agonist-induced downregulation among the individual PKC isoforms may serve as possible mechanisms by which these varied cellular responses are elicited (1, 2) . Thus, the array of isoforms expressed by a cell may determine its response to PKC activation. In addition to the array of isoforms initially expressed, cellular responses requiring chronic activation of the PKC pathway may also be influenced by the different sensitivities of individual isoforms to activation-induced proteolytic downregulation. Alternatively, differences in pathways activated by and distal to PKC that control growth, differentiation, and apoptosis could underlie the diversity of cellular responses to PKC activation.
A role for PKC in modulating growth of breast neoplasms has been suggested from various observations (8) (9) (10) (11) (12) (13) (14) (15) . To directly examine a role for PKC in altering the growth of breast cancer cells, we have generated a MCF-7 human breast cancer cell line that was stably transfected with and overexpresses PKC-a (MCF-7-PKC-a cells). In comparison to the parental MCF-7 cell, the MCF-7-PKC-a cell displays a more transformed, aggressive phenotype as evidenced by an increased proliferative rate, anchorage-independent growth, loss of an epithelioid appearance, downregulation of estrogen receptor expression, and enhanced tumorigenicity with metastatic potential in nude mice ( 16) . These findings demonstrated that alterations in the PKC pathway are associated with significant changes in the proliferative capacity and differentiation status of breast cancer cells.
Given the significant phenotypic alterations observed in MCF-7-PKC-a cells, it was of interest to examine the response of this cell to phorbol ester-stimulated activation of PKCs. Parental MCF-7 cells treated with tetradecanoyl phorbol-13-acetate (TPA) exhibited modest growth inhibition with retention of viability that was associated with sustained induction of Cipl, extensive hypophosphorylation of retinoblastoma (Rb) , and an accumulation of cells in G1. In contrast, TPA induced death of MCF-7-PKC-a cells. MCF-7-PKC-a cells accumulated in G2/M, transiently expressed only low levels of Cipl, and lacked a substantial degree of Rb hypophosphorylation. While eliciting only a modest cytostatic response in MCF-7 cells, bryostatin 1 exerted cytotoxic effects in MCF-7-PKC-a cells at low doses. This response was not seen at higher concentrations of this agent and high doses of bryostatin 1 inhibited MCF-7-PKC-a death induced by TPA. Preceding the onset of death and possibly involved in mediating this process, TPA-treated MCF-7-PKC-a cells expressed high levels of gadd45 mRNA transcripts. Expression of gadd45 was not induced by TPA in MCF-7 cells. Thus, associated with changes in PKC isoform expression was the conversion from a modest cytostatic effect observed in TPA-treated parental MCF-7 cells to death of MCF-7-PKC-a cells exposed to the phorbol ester.
Methods
Cell culture. MCF-7 cells were purchased from the American Type Culture Collection (Rockville, MD). MCF-7-PKC-a cells have been described elsewhere (16) and were generated by stably cotransfecting MCF-7 cells with PKC-a subcloned into the pSV2M(2)6 vector (17) and a neomycin resistance plasmid. The stable transfectants were pooled and expanded as a heterogenous group. Cells stably transfected with the empty pSV2M(2)6 vector were also generated (vector-transfected cells). Cells were grown in DME supplemented with 2 mM glutamine, 10 mM 4-[2-hydroxyethyl] -1-piperazinethanesulfonic acid, 10% fetal calf serum, 50 U/ml penicillin, and 50 jg/ml streptomycin. For cell growth experiments, 7.5 x 103 cells/ml were incubated in 24-well plates with replicates of 6 wells per treatment. Cell counts were done using a Coulter counter (Coulter Corp., Hialeah, FL). Bryostatin 1 was isolated from Bugula neritina as described (18 (pH 7.4) . After postfixation in 1% (wt/vol) osmium tetroxide, cells were dehydrated through a graded series of alcohol and propylene oxide and embedded in Epon. Thick sections were stained with Richardson's stain. Thin sections (< 90 nm) were stained with uranyl acetate and lead citrate and examined with a Jeol-1200 EX electron microscope.
DNA extraction and electrophoresis. Total cellular DNA was isolated as described previously, with minor revisions (19) . Cells (1.5 x 107) were washed and resuspended in 0.5 ml of lysis buffer (50 mM Tris, 10 mM EDTA, 0.5% Triton X-100) with 5 mg/ml proteinase K and incubated at 370C for 12 h. Lysates were then brought to a volume of 2.5 ml with lysis buffer and extracted twice with phenol-chloroform.
DNA was then precipitated with 0. (Fig. 1) . While proliferation of MCF-7-PKC-a cells was inhibited to a greater degree than in parental and vector-transfected MCF-7 cells, the sensitivity of parental/vector-transfected MCF-7 and MCF-7-PKCa cells to phorbol ester-induced growth inhibition was similar.
To examine whether differences in the rate of cell death were responsible for the enhancement in TPA-induced growth inhibition of MCF-7-PKC-a cells, the viability status of phorbol ester-treated cells was examined. Due to extensive clumping of nonadherent, TPA-treated MCF-7-PKC-a cells, it was difficult to quantitate cellular viability using trypan blue exclusion. Viability of cells was examined by FACS® analysis using propidium iodide exclusion as a measure of cellular integrity (24) . Flow Fig. 2 ) or a moderate increase in propidium iodide uptake with varying decreases in forward scatter (see R3 gate in Fig. 2 ). The increase in propidium iodide uptake of cells gating into the RI and R3 regions is consistent with loss of membrane integrity while the reduced forward scatter suggests either cellular condensation or fragmentation. Microscopic analysis of cells sorted from these regions demonstrated that intact, normal appearing cells were contained in the R2 region while debris with stripped nuclei and significantly condensed cells were found in the Ri and R3 regions, respectively (data not shown).
In untreated MCF-7 and MCF-7-PKC-a cells, the vast majority of cells excluded propidium iodide and displayed a degree of forward light scatter indicative of an intact cell (see R2 region in Fig. 2 , A and C). After a 72-h exposure to 10 nM TPA, the majority of parental MCF-7 cells excluded propidium iodide and displayed approximately the same size characteristics as did untreated cells (Fig. 2B ). The proportion of events gated into the RI and R3 regions in TPA-treated parental MCF-7 cells was not significantly increased. In contrast, TPA-treated MCF-7-PKC-a cells displayed a significant reduction in viable, propidium iodide-excluding cells gating into the R2 region. A significant proportion of MCF-7-PKC-a cells exposed to TPA developed either an intense increase in propidium iodide uptake (RI region) or a moderate increase in propidium iodide uptake with a reduction in forward scatter (R3 region). Qualitatively similar decreases in membrane integrity and loss of viability were observed in TPA-treated MCF-7-PKC-a cells using trypan blue exclusion (data not shown). A significant decrease in viability of MCF-7-PKC-a cells exposed to 10 nM TPA, as defined by a loss of propidium iodide-excluding cells gated to the RI region, was observed after a 12-h exposure to 10 nM TPA and was maximal after a 24-48-h exposure to this agent (Fig. 3A) . In contrast, only minimal decreases in viability of parental or vector-transfected cells were seen after TPA treatment. After a 48-h exposure, MCF-7-PKC-a cell death was maximal at a TPA concentration of 10 nM (Fig. 3B ). Thus, increases in cell death were responsible for the more profound growth inhibition observed in TPA-treated MCF-7-PKC-a cells.
Bryostatin I displays concentration-dependent, biphasic effects on growth of MCF-7-PKC-ca cells. Bryostatin 1, a macrocyclic lactone, has completed phase I trials and is currently undergoing clinical evaluation as an antineoplastic agent in phase II studies (25, 26) . While bryostatin 1 is believed to exert its effects by activating the PKC pathway, it can either mimic or antagonize the effects of phorbol esters in a cellspecific fashion (27) . In certain cell types, effects exerted by bryostatin 1 at low doses dissipate as the concentration is increased (28-32). The dose-and cell type-specific responses of bryostatin 1 are thought to be due to preferential up-or downregulation of specific isoforms involved in mediating the effects of TPA and bryostatin 1 (28-33) .
While eliciting only minimal growth inhibition in parental MCF-7 cells that waned at higher concentrations (Fig. 4 A) , bryostatin 1 displayed significant, concentration-dependent antiproliferative effects in MCF-7-PKC-a cells (Fig. 4 B) . The maximal degree of MCF-7-PKC-a growth inhibition induced by TPA was reached at a concentration of 1 nM and remained constant with exposures of 1,000 nM (Fig. 4 B) . In contrast, the growth inhibitory effects of bryostatin 1 significantly waned at concentrations 2100 nM. To examine whether growth inhibition of MCF-7 and MCF-7-PKC-a cells induced by bryostatin 1 was due to a cytostatic or cytotoxic mechanism, cellular viability was examined (Fig. 4 , C and D). MCF-7 cells retained viability upon exposure to 10 nM TPA or bryostatin 1, a concentration that maximally inhibited growth of these cells (Fig. 4  C) . In contrast, MCF-7-PKC-a cells displayed a temporally dependent reduction in viability when exposed to either 10 nM TPA or bryostatin 1 (Fig. 4 D) . As with TPA, MCF-7 and MCF-7-PKC-a cells responded to low doses of bryostatin 1 in qualitatively dissimilar fashions exhibiting cytostatic and cytotoxic responses, respectively.
The ability of high bryostatin 1 concentrations to interfere with TPA-induced death of MCF-7-PKC-a cells was examined.
TPA significantly inhibited growth and reduced the viability of MCF-7-PKC-a cells (Fig. 5, A Cells were harvested and exposed to propidium iodide. Forward light scatter (see ordinate) and propidium iodide uptake (see abscissa) were measured. Cells were gated into separate areas representing: RI, high propidium iodide uptake with variable forward scatter; R2, low propidium iodide uptake and appropriate forward scatter for intact cells; and R3, reduced forward scatter consistent with debris and/or enhanced propidium iodide uptake. This experiment was repeated with similar results. Vector-transfected cells gave identical results to MCF-7 cells.
A). Unlike the extensive cell death that occurred after exposure to 10 nM bryostatin 1, viability of MCF-7-PKC-a cells treated with 1,000 nM bryostatin 1 was essentially unaffected and comparable to that of vehicle-treated cells (Fig. 5 B) . In cells coincubated with these agents, high concentrations of bryostatin 1 exerted dominant effects over TPA and blocked death induced (Fig. 6 A) . TPA treatment caused the cell to flatten (Fig. 6 B) with retention of the normal cellular architecture. MCF-7-PKCa cells proliferated in suspension devoid of an epithelioid morphology (Fig. 6 C) . Exposure of MCF-7-PKC-a cells to TPA (Fig. 6 D) . A minority of TPA-treated MCF-7-PKC-a cells adhered tightly to the plastic surface, displayed prominent vacuolization, and assumed a fibroblast-like appearance (Fig. 6 D) . Exposure to 10 nM bryostatin 1 induced only rare fibroblast-like adherent cells and a much lesser degree of vacuole formation (Fig. 6 E) . Small evaginations from the plasma membrane were seen in cells treated with 10 nM bryostatin 1 (Fig. 6 E) . MCF-7-PKC-a cells treated with 1,000 nM bryostatin 1 in the absence (Fig. 6 F) Fig. 7 A) and MCF-7-PKC-a (Fig. 7 B) cells were examined. TPA treatment of MCF-7-PKC-a cells was associated with nuclear and cellular condensation and cell blebbing (Fig. 7 B) . Similar changes were not seen in TPA-treated MCF-7 cells (Fig. 7 A) . Thus, in contrast to MCF-7 cells, MCF-7-PKC-a cells displayed certain signs indicative of apoptosis (e.g., cellular/nuclear condensation plasma membrane and blebbing) in response to TPA. Electron microscopy indicated that the extensive vacuolization of TPA-treated MCF-7-PKC-a cells was due to lysosomal swelling (Fig. 7 C) . The role, if any, of the lysosomal enlargement in TPA-induced apoptosis of MCF-7-PKC-a cells is uncertain.
Although the development of translucent cytoplasmic vacuoles has been described in apoptosis, lysosomal swelling to the degree observed in TPA-treated MCF-7-PKC-a cells is not usually considered as a morphologic feature of apoptosis (34) . Treatment with 10 nM bryostatin 1 which produced a similar degree of MCF-7-PKC-a death as did 10 nM TPA (Fig. 4 D) was associated with a much lesser degree of lysosomal swelling (Fig. 6 E) . As assessed by staining sectioned cells with Richardson's stain, low-dose bryostatin 1 treatment produced the same cell blebbing (possibly corresponding to the plasma membrane evaginations seen with inverted microscopy) and cellular/nuclear condensation (data not shown). The lysosomal swelling seen in TPA-treated MCF-7-PKC-a cells could be a unique morphologic feature associated with the death of these cells. Alternatively, this event could be due to the differences in PKC isoform expression between MCF-7-PKC-a and MCF-7 cells and their effect on the lysosomal response to TPA-induced activation. However, the ability of 10 nM TPA and bryostatin 1 to elicit different degrees of lysosomal swelling in MCF-7-PKCa cells and yet to stimulate a similar extent of cell death suggests that the pronounced swelling was due to a primary alteration in the lysosomal response to TPA rather than being associated with the death process.
Given the association of DNA fragmentation into oligonucleosomal units with apoptosis, this parameter was examined in MCF-7-PKC-a cells (Fig. 8) . Despite the morphologic evidence suggestive of apoptosis in TPA-treated MCF-7-PKC-a cells, degradation of DNA into oligonucleosomal units was not detected after phorbol ester treatment of these cells. Certain cells undergoing apoptosis have been reported to exhibit DNA degradation yielding high molecular weight fragments in the absence of further degradation to form oligonucleosomal units (35) . Thus our inability to detect DNA degradation into oligonucleosomal units does not necessarily imply the absence of DNA fragmentation in TPA-treated MCF-7-PKC-a cells.
TPA induces dissimilar cell cycle alterations in MCF-7 and MCF-7-PKC-ar cells. A time-dependent accumulation of MCF-7 cells in G1 was observed with TPA treatment (Fig. 9 A) . In contrast, TPA treatment elicited a prominent accumulation of Phorbol Esters Induce Death of MCF-7 Cells (Fig. 9 B) . Thus, the dissimilar response of MCF-7 and MCF-7-PKC-a cells to TPA suggested that differences exist in the factors mediating phorbol esterinduced modulation of cell cycle check points.
MCF-7-PKC-a cells in G2/M
MCF-7-PKC-a cells lack p53. Given the prominent role of p53 in controlling cell cycle progression from GI to S phase and its ability to stimulate cell death (36) (37) (38) - Figure 8 . TPA-treated MCF-7-PKC-a cells undergo death without forming an oligonucleosomal DNA ladder. MCF-7 and MCF-7-PKC-a cells were treated for varying times with 100 nM TPA (see above the gel). DNA was extracted and subjected to agarose electrophoresis. The migration of molecular weight indicators is shown on the far right. This experiment was repeated on several occasions with similar results. Vector-transfected cells responded to TPA treatment in a similar manner as did MCF-7 cells.
tected in vector-transfected and MCF-7 cells (Fig. 10) . However, levels of p53 mRNA transcripts were negligible in MCF-7-PKC-a cells (Fig. 10 A) . Using Western blot analysis, a concomitant reduction in the content of p53 protein was observed in MCF-7-PKC-a cells relative to those levels found in MCF-7 and vector-transfected cells (Fig. 10 B) . To examine whether a gross p53 gene rearrangement occurred in MCF-7-PKC-a cells that could explain its loss of expression, Southern blot analysis was performed. The use of multiple restriction enzymes that cut within the p53 locus (BamHI, EcoRI, HindIII, and XbaI) failed to reveal any gross rearrangement of the p53 gene (data not shown). To directly assess the transcriptional status of factors controlling expression of p53, transient transfection assays were performed using a p53 promoter-reporter CAT construct (pO.5 CAT). The p53 promoter region subcloned into the reporter construct includes nucleotides -320 to +210 relative to the transcriptional start site and has been shown to be activated by p53 (22) . After normalization to 3-galactosidase activity to control for differences in transfectional efficiency, a significant basal induction of CAT expression controlled by the p53 promoter was evident in MCF-7 cells (Fig.  11 A) . In MCF-7-PKC-a cells, basal levels of pO.5 CAT activity were negligible (Fig. 11 A) CAT activity by p53 expression in MCF-7-PKC-a cells was specific since cotransfection with the inactive p53 mutant failed to enhance this activity. Thus, the marked reduction in p53 mRNA transcripts contained in MCF-7-PKC-a cells could, in part, be explained by a reduction in the transcription of this gene as indicated by the decreased p53-promoter CAT reporter activity in these cells. Functional p53 activity was assessed using the PG-13-CAT construct that contains multiple copies of the consensus p53 response element. In MCF-7 cells transiently transfected with the PG-13-CAT construct, significant activation of the reporter was evident (Fig. 11 B) . MCF-7 cells transfected with the mutant, non-p53-responsive construct (MG-1S-CAT) displayed negligible levels of CAT activity. In MCF-7-PKC-a cells, similar low levels of CAT activity were expressed from either PG-13-CAT or MG-1S-CAT. Thus, MCF-7-PKC-a cells displayed a large reduction in functional p53-directed transcriptional activity.
Phorbol esters induce Cip] expression in MCF-7 cells while gadd45 is strongly induced in MCF-7-PKC-a cells. Given the ability of Cipl/WAFl/p21 to arrest cells in GO/GI (39, 40) and the association of Cipl and gadd45 expression with cell death (41-45), we examined their expression in TPA-treated MCF-7 and MCF-7-PKC-a cells (Fig. 12) . TPA-treated MCF- (Fig. 12 A) . A modest induction of CipI was detected in TPAtreated MCF-7-PKC-a cells. However, TPA failed to stimulate a sustained expression of Cipl in MCF-7-PKC-a cells. In contrast, TPA treatment of MCF-7-PKC-a cells markedly stimulated expression of gadd45 (Fig. 12 A) . Only a modest TPAinduced increase in gadd45 was detected in MCF-7 cells. The increase in gadd45 in MCF-7-PKC-a cells (2-4 h) temporally preceded the onset of decreases in viability occurring at 12 h (Fig. 3 A) . Using nuclear run-on analysis, basal transcriptional activity of gadd45 was shown to be significantly increased (t 8.8-fold) in MCF-7-PKC-a cells relative to MCF-7 cells (Fig. 12 B) . While gadd45 transcription was not stimulated by TPA in MCF-7 cells, a 2.6-fold increase in transcription of this gene was observed in MCF-7-PKC-a cells within a 30-min exposure to TPA (Fig. 12 B) . Transcription of gadd45 in MCF-7-PKC-a cells remained elevated above the basal levels even 12 h after exposure to TPA. The inability of TPA to induce gadd45 expression in MCF-7-PKC-a cells pretreated with cycloheximide demonstrated that induction of this gene required ongoing protein synthesis (Fig. 12 C) .
TPA-induced expression of Cip] in MCF-7 cells was not associated with an increase in p53-dependent transcriptional activity. Expression of Cipl and gadd45 can be mediated by a p53-dependent pathway (39-41, 46, 47) . To examine whether TPA used a p53-dependent mechanism to induce expression of these genes, the content of p53 and functional status of this pathway were analyzed in TPA-treated cells. TPA treatment of MCF-7 cells elicited a temporally dependent reduction in p53 mRNA transcripts (Fig. 13 A) . In MCF-7-PKC-a cells, p53 mRNA transcripts were not detected in the basal state nor were they induced upon TPA treatment. To assess the functional consequences of the TPA-induced reduction in p53 mRNA transcripts in MCF-7 cells, expression of the p53-responsive PG-13-CAT construct was examined after TPA treatment (Fig. 13,  B and C) . Treatment of MCF-7 cells with 10 or 100 nM TPA reduced the activity of the p53-responsive, PG-13-CAT construct (Fig. 13 C) . Given the possibility that TPA may acutely activate and then later repress p53-dependent transcriptional activity, the effects of varying the duration of TPA exposure to MCF-7 cells transiently transfected with the PG-13 reporter were examined. Whether added for the entire period (48 h) or only the final 24 h, TPA did not activate the PG-13 reporter construct and, in fact, possessed significant inhibitory properties (Fig. 13 C) . Under these treatment conditions, TPA did not stimulate activation of the PG-13-CAT reporter construct. Thus, despite the significant Cipl induction in TPA-treated MCF-7 cells, p53-dependent transcriptional activity diminished after exposure to the phorbol ester. Rb hypophosphorylation in TPA-treated MCF-7 and MCF-7-PKC-a cells. Cipl inhibition of the cyclin-dependent kinase activities leading to a reduced level of Rb phosphorylation is involved in mediating growth arrest at the G1-S boundary (48) . To examine whether differences in Rb phosphorylation could explain the altered cell cycle progression in TPA-treated MCF-7-PKC-a cells, Western blot analysis was done to determine the phosphorylation status of this protein (Fig. 14) . Nearly complete hypophosphorylation of Rb was induced by TPA treatment in MCF-7 cells. In contrast, TPA treatment of MCF-7-PKC-a cells produced only a partial degree of Rb hypophosphorylation. Thus, extensive hypophosphorylation of Rb in TPA-treated MCF-7 cells was associated with sustained, high levels of Cipl expression. In addition, the increase in Cipl expression preceded the onset of Rb hypophosphorylation in MCF-7 cells. The transient expression of Cipl in TPA-treated MCF-7-PKC-a cells at only 4 and 8 h after TPA exposure was associated with a much reduced degree of Rb hypophosphorylation relative to that seen in parental MCF-7 cells. It is unclear as to whether the lesser degree of induction or the transient nature of Cip expression was responsible for the lesser degree of Rb hypophosphorylation in TPAtreated MCF-7-PKC-a cells.
Discussion
In MCF-7 cells, phorbol esters and, to a lesser degree, bryostatin I elicit a modest degree of growth inhibition associated with retention of viability. However, overexpression of PKC-a in MCF-7 breast cancer cells, either directly or indirectly due to other phenotypic alterations occurring in these cells, lead to cell death in response to phorbol esters and low doses of bryostatin 1 rather than the cytostatic effect elicited in the parental MCF-7 cell. It remains unresolved as to whether overexpression of PKC-a or the concurrent alterations in the endogenous expression of other PKC isoforms are responsible for initiating the death signal. Although generated by overexpression of PKC-a, MCF-7-PKC-a cells display increases in the and 0 isoforms, moderate decreases in PKC-6 and -t, and a total abolition of PKC-iq expression (reference 16 and manuscript in preparation). Thus, with these concomitant alterations in other PKCs, it is difficult from the current data to ascribe a direct role for a or another specific isoform in stimulating death. Lastly, it remains to be determined whether the mechanisms responsible for the dissimilar response of TPA-treated MCF-7-PKC-a cells reside solely within the PKC pathway or are due to alterations in signaling pathways distal to and stimulated by PKC activation that regulate induction of death. Nonetheless, these data suggest that alterations in PKC isoform expression can influence the molecular switch controlling the decision of a breast cancer cell to undergo death or differentiation in response to activation of this pathway.
The ability of bryostatin 1 to exert effects at low doses that wane or disappear at higher doses has been amply documented in various cell types (27) (28) (29) (30) (31) (32) . In addition, the capacity for high doses of bryostatin 1 to antagonize the cellular effects of TPA has been described previously (27-29, 32, 33 (27, 28) . In other cells, the biphasic cellular response of bryostatin 1 correlates with depletion of a specific PKC isoform at low concentrations of this agent and abrogation of downregulation of the same isoform in cells treated with higher doses of bryostatin 1 (32, 33 (47) . However, TPA induction of gadd45 in MCF-7-PKC-a cells occurred in the absence of detectable p53 levels or functional p53-mediated transcriptional activity. An AP-1 site located in the third intron near the p53 site is also present in the gadd45 gene (47 PKC-a cells, these findings demonstrate the existence of a phorbol ester-activated, p53-independent pathway that can regulate expression of this gene.
While MCF-7 cells contained readily measurable amounts of p53 mRNA transcripts and protein, this transcriptional factor was not detected in MCF-7-PKC-a cells. Southern blot analysis did not identify a gross gene rearrangement that could account for the absence of p53. Transient transfection analysis using the p53 promoter-CAT construct demonstrated an almost complete lack of transcriptional activation of this promoter in MCF-7-PKC-a cells relative to the levels detected in MCF-7 cells.
Thus, the decline of p53 in MCF-7-PKC-a cells was mediated, gene. Given the predominance of other well described mechanisms that inhibit p53 function in human tumors, the significance of whether a decrease in the transcription of this gene as a clinically important phenomenon in human neoplasia remains uncertain. However, these findings do suggest an interaction between the PKC pathway and p53 transcriptional regulation. Lending further support for such an interaction was the ability of TPA to downregulate p53 mRNA transcripts with a concomitant decrease in p53 functional activity as assessed by the transient transfection studies with the PG-13 CAT reporter in MCF-7 cells. A similar TPA-induced decrease in p53 mRNA transcripts has been noted in HeLa and A549 cells (50) .
In MCF-7 cells, TPA treatment rapidly stimulated increases in expression of Cipl. The functional significance of induction of this cyclin-dependent kinase interacting protein was apparent in the hypophosphorylated state of Rb and the accumulation of MCF-7 cells in G1. Transcriptional activation of Cipl can occur via a p53-dependent mechanism (39) (40) (41) . Recently, p53-independent modes of inducing Cipl expression have been described (51) (52) (53) 
